Neurotech Pharmaceuticals, Inc. has announced FDA approval of ENCELTO (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel). ENCELTO is the First and Only FDA-approved first and only treatment for MacTel. MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly impacting patients’ quality of [Read More]
Category: Latest News
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo may help people with DME maintain their vision Approval marks the second indication for Susvimo in addition to wet, or neovascular age-related macular [Read More]
Current Technology for the Blind and Visually Impaired
Assistive technology for the visually impaired is available from low-tech optical and non-optical aids to electronics and digital technology. Visually impaired and blind individuals have a tremendous number of options to eyesight, depending upon their needs, goals, and financial situations. “Ethyl”, for example, likes to talk on her landline phone. When walking, she uses a [Read More]
Macular Telangiectasia (MacTel)
Prevent Blindness is currently developing new educational materials on macular telangiectasia. We recognize that no one understands the impact of MacTel better than those who are living with it, so we want to hear from you! If you have MacTel and would like to contribute you insight and experiences to help us create effective resources, [Read More]
Opportunity to Participate in Paid Geographic Atrophy Study
Global Perspectives is looking for people with advanced dry AMD (age-related macular degeneration), also known as geographic atrophy (GA). The purpose of this study is to understand patients’ views and preferences related to treatments for geographic atrophy including some that are in development. No treatments will be administered in this study, as only opinions are [Read More]